Detalles de la búsqueda
1.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32683565
2.
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Lancet Oncol
; 20(11): 1587-1601, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31575503
3.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Lancet Oncol
; 16(1): 25-35, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25524798
4.
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.
Clin Cancer Res
; 28(4): 629-636, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887261
Resultados
1 -
4
de 4
1
Próxima >
>>